Asarfi Hospital

Asarfi Hospital

136.00
+7.00
(5.43%)
Market Cap
253.80 Cr
EPS
5.37
PE Ratio
21.99
Dividend Yield
0.00 %
52 Week High
153.90
52 Week Low
52.84
PB Ratio
3.20
Debt to Equity
0.53
Sector
Hospitals
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%

Company News

View All News
Caret
positive
Asarfi Hospital Reports 56% Revenue Growth and Secures Rs 8.25 Crore Loan for ExpansionAug 07, 2025
Asarfi Hospital Limited reported quarterly results for the quarter ended June 30, 2025, showing strong financial performance. Standalone revenue from operations increased 56% year-over-year to Rs 3,566 lakhs, while consolidated revenue reached Rs 3,568 lakhs. Standalone profit after tax grew 109% to Rs 320 lakhs, and consolidated PAT increased 115% to Rs 312 lakhs. EBITDA margins improved to 20% for both standalone and consolidated results. The company secured loan sanction of Rs 8.25 crores from HDFC Bank, comprising a Rs 5.25 crore term loan for educational building construction and Rs 3 crore working capital loan for Asarfi Cancer Unit expansion. The hospital operates 315 beds across two facilities - a 250-bed Super-Specialty unit and 65-bed Cancer unit. Occupancy rates improved with the Super-Specialty Hospital at 64% versus 57% in the previous year, and Cancer Hospital at 42% versus 24%. The company also signed an MoU with Gleneagles Hospital Chennai to establish Jharkhand's first Multi-Organ Transplant Unit.
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,113.20
#1 1,08,375.20
90.16
7,184.10
#1 28.68
1,076
30.34
34.65
7,441.00
1,06,530.10
68.01
#1 21,994.30
14.76
#1 1,505
39.78
32.66
989.65
73,215.80
80.84
7,849.70
13.25
809
#1 53.33
58.73
1,731.50
35,509.70
#1 44.78
5,575.00
12.29
790
-2.38
43.91
1,304.60
35,319.10
61.56
3,771.40
12.59
481
49.58
41.83
630.85
32,483.60
91.44
4,286.70
15.12
337
-98.18
50.92
687.90
28,015.70
74.62
3,067.00
21.98
415
-10.71
33.27
1,343.60
13,771.40
53.07
1,566.90
17.46
244
35.52
25.21
1,500.30
9,971.90
50.98
1,290.20
17.77
194
-1.57
61.60
650.10
9,070.50
247.05
2,257.70
17.03
49
-55.88
43.42
Forecast
Actual
Growth Rate
Revenue Growth
48.78 %
Net Income Growth
152.38 %
Cash Flow Change
-116.69 %
ROE
120.98 %
ROCE
83.68 %
EBITDA Margin (Avg.)
-6.37 %

Quarterly Financial Results

Quarterly Financials
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Jun 2025
Revenue
21
24
24
32
34
39
37
Expenses
16
20
18
24
26
29
29
EBITDA
5
4
5
8
8
10
8
Operating Profit %
20 %
16 %
21 %
22 %
21 %
15 %
20 %
Depreciation
3
4
3
3
3
3
3
Interest
1
1
1
1
1
1
1
Profit Before Tax
1
-1
2
4
4
5
4
Tax
1
-1
0
1
1
2
1
Net Profit
-0
-0
2
3
3
4
3
EPS in ₹
-0.03
-0.18
0.74
1.45
1.36
1.82
1.59

Balance Sheet

Balance Sheet
2024
2025
Total Assets
154
164
Fixed Assets
94
102
Current Assets
46
59
Capital Work in Progress
0
2
Investments
0
0
Other Assets
60
60
Total Liabilities
154
164
Current Liabilities
44
41
Non Current Liabilities
39
42
Total Equity
70
81
Reserve & Surplus
51
61
Share Capital
20
20

Cash Flow

Cash Flow
2024
2025
Net Cash Flow
-1
1
Investing Activities
-63
-7
Operating Activities
26
-4
Financing Activities
36
13

Share Holding

% Holding
Mar 2023
Jul 2023
Sept 2023
Mar 2024
Sept 2024
Mar 2025
Jun 2025
Promoter
83.03 %
61.17 %
61.17 %
61.17 %
61.17 %
61.17 %
61.17 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.10 %
DIIs
0.00 %
0.37 %
3.25 %
2.33 %
1.95 %
2.92 %
3.18 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
0.00 %
23.73 %
27.40 %
31.63 %
32.99 %
30.86 %
29.89 %
Others
16.97 %
14.74 %
8.18 %
4.87 %
3.89 %
5.05 %
5.66 %
No of Share Holders
37
1,248
706
1,261
1,284
1,262
1,176

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
30 Jan 2024 EXTRAORDINARY GENERAL MEETING Extraordinary General Meeting
NA
30 Jan 2024 83.07 94.14
13 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
13 Sept 2024 62.88 63.15
30 Oct 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
30 Oct 2024 59.99 63.60
31 Jan 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
31 Jan 2025 93.67 94.88
08 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
08 May 2025 89.81 94.41
07 Aug 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Aug 2025 131.05 128.25
12 Sept 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
12 Sept 2025 126.50 147.00

Announcements

Board Meeting Outcome for Intimation Of Appointment Of Cost Auditor6 days ago
Disclosure Regarding Clerical Error In Debtors Ageing Statement In The Financial Statements For The Year Ended March 31 2025Sep 20, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 13, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 12, 2025
Reg. 34 (1) Annual Report.Aug 21, 2025
Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) 2015.Aug 20, 2025
Board Meeting Intimation for Intimation Of Board Meeting For Consideration And Approval Of BoardS Report And Notice Of AGM.Aug 12, 2025
Financial Result For Quarter Ended 30Th June2025Aug 07, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationAug 07, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 07Th August 2025 And Submission Of Unaudited Financial Results For The Quarter Ended 30Th June 2025.Aug 07, 2025
Board Meeting Outcome for Reply To Discrepancy - Reason For Delay In Intimation Of Appointment Of Company Secretary And Compliance OfficerAug 06, 2025
Board Meeting Intimation for Consider And Approve The Unaudited Financial Results Of The Company For The Quarter Ended 30Th June2025.Jul 31, 2025
Closure of Trading WindowJun 27, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 06, 2025
Appointment of Company Secretary and Compliance OfficerJun 04, 2025
Board Meeting Outcome for Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015 - Appointment Of Compliance Officer Cum Company Secretary.Jun 04, 2025
Integrated Filing (Financial)May 24, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 19, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 14, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 12, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 09, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationMay 09, 2025
Board Meeting Outcome for Outcome Of Board Meeting Held On 08Th May 2025 And Submission Of Standalone & Consolidated Audited Financial Results For The Quarter Ended & Year Ended 31St March 2025 As Per SEBI (Listing Obligations And Disclosure Requirements)May 08, 2025
Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of SEBI Listing Regulations 2015.May 02, 2025
Closure of Trading WindowMar 29, 2025
Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 28, 2025
Intimation Of Material Event-High Court Jharkhand Order Civil Litigation Related To Cancer Hospital Land.Mar 13, 2025
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerMar 03, 2025
Announcement under Regulation 30 (LODR)-Investor PresentationJan 31, 2025
Outcome Of Board Meeting Held On 31St January 2025 And Submission Of Unaudited Financial Results For The Quarter Ended 31St December 2024 As Per SEBI (Listing Obligations And Disclosure Requirements) Jan 31, 2025
Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of SEBI Listing Regulations 2015 To Consider And Approve The Unaudited Financial Results For The Quater Ended 31St Dec2025.Jan 23, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 09, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 06, 2024
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 01, 2024
Intimation Of Material Event - Possession & Registry Of Land.Nov 01, 2024
Announcement under Regulation 30 (LODR)-Investor PresentationOct 30, 2024
Outcome Of Board Meeting Held On 30Th October, 2024 And Submission Of Unaudited Financial Results For The Half Year Ended 30Th September, 2024 As Per SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.Oct 30, 2024
Board Meeting Intimation for Intimation Under Regulation 29(1)(A) Of SEBI Listing Regulations, 2015.Oct 22, 2024
Statement Of Deviation Or Variation In The Use Of Proceeds Of Initial Public IssueOct 10, 2024
Announcement Regarding Expansion Of Services Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.Oct 10, 2024
Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing Obligation And Disclosure Requirement) 2015.Oct 07, 2024
Announcement Regarding Grant Of Approval From Pharmacy Council Of India For D. Pharm Course Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015,Sep 30, 2024
Closure of Trading WindowSep 26, 2024
Shareholder Meeting / Postal Ballot-Scrutinizer''s ReportSep 14, 2024
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 13, 2024
Intimation Regarding Revision In Credit Rating.Sep 09, 2024
Additional Disclosure As Required Under Regulation 30 Of SEBI (LODR) Regulations,2015.Aug 23, 2024
Reg. 34 (1) Annual Report.Aug 22, 2024
Board Meeting Outcome for Outcome Of Board Meeting Under Regulation 30 Of SEBI (Listing ObligationAnd Disclosure Requirement) 2015.Aug 20, 2024
Board Meeting Intimation for BOARD MEETINGAug 13, 2024

Technical Indicators

RSI(14)
Neutral
54.87
ATR(14)
Volatile
5.66
STOCH(9,6)
Neutral
34.43
STOCH RSI(14)
Neutral
27.07
MACD(12,26)
Bearish
-0.80
ADX(14)
Weak Trend
20.60
UO(9)
Bearish
55.83
ROC(12)
Downtrend And Accelerating
-2.63
WillR(14)
Neutral
-44.13